Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues

Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment‐naive patients with chronic hepatitis B virus (HBV) infection but experience in nucleoside/nucleotide analogue (NA)‐experienced patients is limited. In this retrospective multicenter study we therefore assessed the long‐term efficacy of TDF monotherapy in patients with prior failure or resistance to different NA treatments. Criteria for inclusion were HBV DNA levels >4.0 log10 copies/mL at the start and a minimum period of TDF therapy for at least 6 months. In all, 131 patients (mean age 42 ± 12 years, 95 male, 65% hepatitis B e antigen [HBeAg]‐positive) were eligible. Pretreatment consisted of either monotherapy with lamivudine (LAM; n = 18), adefovir (ADV; n = 8), and sequential LAM‐ADV therapy (n = 73), or add‐on combination therapy with both drugs (n = 29). Three patients had failed entecavir therapy. Resistance analysis in 113 of the 131 patients revealed genotypic LAM and ADV resistance in 62% and 19% of patients, respectively. The mean HBV DNA level at TDF baseline was 7.6 ± 1.5 log10 copies/mL. The overall cumulative proportion of patients achieving HBV DNA levels <400 copies/mL was 79% after a mean treatment duration of 23 months (range, 6–60). Although LAM resistance did not influence the antiviral efficacy of TDF, the presence of ADV resistance impaired TDF efficacy (100% versus 52% probability of HBV DNA <400 copies/mL, respectively). However, virologic breakthrough was not observed in any of the patients during the entire observation period. Loss of HBeAg occurred in 24% of patients and HBsAg loss occurred in 3%. No significant adverse events were noticed during TDF monotherapy. Conclusion: TDF monotherapy induced a potent and long‐lasting antiviral response in NA‐experienced patients with previous treatment failure. Our data may have implications for current add‐on strategies. (HEPATOLOGY 2009.)

[1]  A. Lok,et al.  Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. , 2008, Journal of hepatology.

[2]  M. Manns,et al.  Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. , 2007, Zeitschrift fur Gastroenterologie.

[3]  V. Johnson,et al.  Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 , 2006, Hepatology.

[4]  R. Bruno,et al.  Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection , 2006, AIDS.

[5]  T. Berg,et al.  Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy , 2006, Hepatology.

[6]  Michael D. Miller,et al.  Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus , 2006, Antimicrobial Agents and Chemotherapy.

[7]  Huiling Yang,et al.  In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents , 2006, Antiviral therapy.

[8]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[9]  E. Clercq,et al.  Acyclic nucleoside phosphonates: a key class of antiviral drugs , 2005, Nature Reviews Drug Discovery.

[10]  H. Janssen,et al.  Viral dynamics during tenofovir therapy in patients infected with lamivudine‐resistant hepatitis B virus mutants , 2005, Journal of viral hepatitis.

[11]  Huiling Yang,et al.  Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV , 2005, Antiviral therapy.

[12]  T. Berg,et al.  Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection , 2004, Hepatology.

[13]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[14]  C. Katlama,et al.  In Vitro Susceptibility of Lamivudine-Resistant Hepatitis B Virus to Adefovir and Tenofovir , 2003, Antiviral therapy.

[15]  R. Tubiana,et al.  Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. , 2003, The New England journal of medicine.

[16]  V. Soriano,et al.  Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. , 2002, AIDS.

[17]  T. Berg,et al.  Tenofovir treatment in patients with lamivudine‐resistant hepatitis B mutants strongly affects viral replication , 2002, Hepatology.

[18]  D. Richman,et al.  Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.

[19]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[20]  S. Löfdahl,et al.  Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. , 1992, The Journal of general virology.

[21]  J. Stockman,et al.  Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B , 2010 .

[22]  T. Berg,et al.  76 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN SUBJECTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL (ADV) , 2008 .

[23]  D. Richman,et al.  Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.